Results from the ADRIATIC trial showed that treatment with Imfinzi after standard-of-care concurrent chemoradiation improved overall and progression-free survival in patients with limited-stage small cell lung cancer.
Imfinzi improves survival in patients with limited-stage small cell lung cancer, according to Phase 3 data presented at ASCO
Leave a comment
